Immunomedics (IMMU) says it's created two new classes of bispecific antibodies as the...

|By:, SA News Editor

Immunomedics (IMMU) says it's created two new classes of bispecific antibodies as the Dock-And-Lock complexes using the company's patented platform technology. These bispecific antibodies exhibited potent cell killing activity against lymphoma cell lines in vitro, with superior pharmacokinetic profiles and a higher effector functions.